Lyell Immunopharma (LYEL) Stifel 2026 Targeted Oncology Virtual Forum summary

Strategic overview and pipeline focus

• Focused on next-generation cell therapies for hematologic malignancies and solid tumors, with two lead clinical programs targeting large B-cell lymphoma and metastatic colorectal cancer.

• Owns a dedicated manufacturing facility, enabling control over production and launch scalability.

Ronde-cel product differentiation and clinical data

• Ronde-cel uses a tandem CAR construct targeting both CD19 and CD20, designed for more complete and durable responses by reducing antigen escape.

• Enriches for CD62L+ T cells to enhance persistence and safety.

• Demonstrated a 93% overall response rate and 76% complete response rate in third-line+ large B-cell lymphoma, with median progression-free survival of 18 months, outperforming approved CD19 CARs.

• Second-line cohort, primarily primary refractory patients, showed 83% overall response and 61% complete response rates, exceeding comparator data.

Clinical development and regulatory strategy

• PiNACLE single-arm trial in third-line+ setting targets 120 enrolled, 100 treated patients for pivotal data; top-line data expected mid-2027, BLA submission by end of 2027.

• Consistent and promising data across presentations; next major update expected in the second half of the year.

• Regulatory interactions suggest potential for full or accelerated approval based on single-arm data, supported by ongoing head-to-head randomized controlled trial versus Breyanzi or Yescarta.

• RMAT designation in both second and third-line settings reflects regulatory recognition of meaningful data.